Tags

Type your tag names separated by a space and hit enter

CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis

Links

  • NCBI Bookshelf
  • Publisher

    Canadian Agency for Drugs and Technologies in Health
    Ottawa (ON)

    Language

    eng

    PubMed ID

    31206289

    Citation

    CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Canadian Agency for Drugs and Technologies in Health, 2019, Ottawa (ON).
    CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
    (2019). In CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health;
    CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.
    * Article titles in AMA citation format should be in sentence-case
    TY - BOOK T1 - CADTH Canadian Drug Expert Committee Recommendation: Edaravone (Radicava — Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of amyotrophic lateral sclerosis Y1 - 2019/03// PY - 2019/6/18/pubmed PY - 2019/6/18/medline PY - 2019/6/18/entrez PB - Canadian Agency for Drugs and Technologies in Health CY - Ottawa (ON) UR - https://www.unboundmedicine.com/medline/citation/31206289/CADTH_Canadian_Drug_Expert_Committee_Recommendation:_Edaravone_(Radicava_—_Mitsubishi_Tanabe_Pharma_Corporation):_Indication:_For_the_treatment_of_amyotrophic_lateral_sclerosis L2 - https://www.ncbi.nlm.nih.gov/books/NBK542405 DB - PRIME DP - Unbound Medicine ER -
    Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
    Unbound MEDLINE
    Unbound PubMed app for WindowsUnbound PubMed app for MAC OSX Yosemite Macbook Air pro